Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

ERK1/2 Antikörper (AA 300-380)

MAPK1/3 Reaktivität: Human, Maus, Ratte WB, ELISA, IHC (p), IF Wirt: Kaninchen Polyclonal unconjugated
Produktnummer ABIN7206459
  • Target Alle ERK1/2 (MAPK1/3) Antikörper anzeigen
    ERK1/2 (MAPK1/3) (Mitogen-Activated Protein Kinase 1/3 (MAPK1/3))
    Bindungsspezifität
    • 56
    • 41
    • 30
    • 30
    • 16
    • 12
    • 12
    • 10
    • 8
    • 6
    • 4
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 300-380
    Reaktivität
    • 199
    • 169
    • 166
    • 23
    • 23
    • 18
    • 7
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Human, Maus, Ratte
    Wirt
    • 143
    • 58
    • 4
    Kaninchen
    Klonalität
    • 139
    • 66
    Polyklonal
    Konjugat
    • 99
    • 12
    • 9
    • 9
    • 8
    • 8
    • 8
    • 8
    • 8
    • 5
    • 5
    • 5
    • 5
    • 5
    • 4
    • 3
    • 1
    • 1
    • 1
    • 1
    Dieser ERK1/2 Antikörper ist unkonjugiert
    Applikation
    • 157
    • 65
    • 51
    • 50
    • 50
    • 37
    • 25
    • 22
    • 22
    • 13
    • 7
    • 4
    • 4
    • 3
    • 2
    Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (IF)
    Verwendungszweck
    ERK 1/2 Polyclonal Antibody
    Spezifität
    ERK 1/2 Polyclonal Antibody detects endogenous levels of ERK 1/2 protein.
    Aufreinigung
    The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen
    Immunogen
    Synthesized peptide derived from the C-terminal region of human ERK 1/2 at AA range: 300-380
    Isotyp
    IgG
    Top Product
    Discover our top product MAPK1/3 Primärantikörper
  • Applikationshinweise
    Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB (1:500-1:2000), IF (1:50-1:200), IHC-P (1:100-1:300), ELISA (1:10000). Not yet tested in other applications.
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    1 mg/mL
    Buffer
    PBS containing 50 % Glycerol, 0.5 % BSA and 0.02 % Sodium Azide.
    Konservierungsmittel
    Sodium azide
    Vorsichtsmaßnahmen
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    -20 °C
    Informationen zur Lagerung
    Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.
  • Target
    ERK1/2 (MAPK1/3) (Mitogen-Activated Protein Kinase 1/3 (MAPK1/3))
    Andere Bezeichnung
    ERK 1/2 (MAPK1/3 Produkte)
    Synonyme
    erk1/2 antikoerper, mitogen-activated protein kinase antikoerper, erk1/2 antikoerper
    Hintergrund
    Rabbit Anti-ERK 1/2 Polyclonal Antibody,MAPK3, ERK1, PRKM3, Mitogen-activated protein kinase 3, MAP kinase 3, MAPK 3, ERT2, Extracellular signal-regulated kinase 1, ERK-1, Insulin-stimulated MAP2 kinase, MAP kinase isoform p44, p44-MAPK, Microtubule-associated protein 2 kinase, p,Mitogen-activated protein kinase 3 encoded by MAPK3 is a member of the MAP kinase family. MAP kinases, also known as extracellular signal-regulated kinases (ERKs), act in a signaling cascade that regulates various cellular processes such as proliferation, differentiation, and cell cycle progression in response to a variety of extracellular signals. This kinase is activated by upstream kinases, resulting in its translocation to the nucleus where it phosphorylates nuclear targets. Alternatively spliced transcript variants encoding different protein isoforms have been described.,Mitogen-activated protein kinase 3
    Gen-ID
    5595
Sie sind hier: